Bioventus (NYSE:BVS) Updates FY 2025 Earnings Guidance

Bioventus (NYSE:BVS) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.640-0.680 for the period, compared to the consensus estimate of 0.550. The company issued revenue guidance of $560.0 million-$570.0 million, compared to the consensus revenue estimate of $554.8 million.

Analysts Set New Price Targets

Separately, JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and increased their price objective for the stock from $12.00 to $13.00 in a research report on Tuesday, December 17th.

Bioventus Price Performance

Shares of NYSE BVS opened at $8.76 on Tuesday. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. The company has a market capitalization of $710.92 million, a PE ratio of -14.36 and a beta of 0.86. The firm has a fifty day simple moving average of $10.12 and a 200 day simple moving average of $11.01. Bioventus has a twelve month low of $3.90 and a twelve month high of $14.38.

Insider Transactions at Bioventus

In other Bioventus news, SVP Katrina J. Church sold 2,535 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $10.53, for a total transaction of $26,693.55. Following the transaction, the senior vice president now owns 47,264 shares in the company, valued at approximately $497,689.92. This represents a 5.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Robert E. Claypoole sold 28,786 shares of the firm’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $9.10, for a total value of $261,952.60. Following the transaction, the chief executive officer now owns 64,964 shares in the company, valued at approximately $591,172.40. This trade represents a 30.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 52,932 shares of company stock valued at $512,511 in the last 90 days. 32.90% of the stock is currently owned by corporate insiders.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.